ArticleEClinicalMedicine2024

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial.

Maria Pilar Ruiz Seco et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.